Earnings ·
Lineage Cell Therapeutics reported second quarter 2026 financial results, posting net income of $1.5 million ($0.01…
LCTXLineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics reported second quarter 2026 financial results, posting net income of $1.5 million ($0.01 basic EPS), a significant turnaround from the $30.5 million loss in the prior year period driven by non-cash warrant liability remeasurement gains and the absence of a previous impairment charge. Total revenues declined to $1.1 million from $2.8 million due to lower collaboration revenue recognition under the Roche Agreement, while operating expenses fell to $10.0 million as R&D costs rose to $4.8 million and G&A increased to $5.2 million. The company holds $50.8 million in cash and marketable securities, sufficient to fund operations through Q3 2028. Clinically, the firm highlighted sustained positive Phase 1/2a data for RG6501 (OpRegen) at three years, advanced its wholly-owned COR1 corneal therapy program into animal testing, and initiated enrollment in the OPC1 spinal cord injury DOSED study. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic cell therapies for serious medical conditions.